【作者】 寿春晖；

【导师】 于吉人；

【作者基本信息】 浙江大学 ， 胃肠外科， 2011， 硕士

【摘要】 目的研究伊马替尼对中危或高危胃肠道间质瘤患者的术后辅助治疗效果。方法回顾性分析2007年4月至2009年6月于我院接受根治性手术的中危或高危胃肠道间质瘤患者,接受伊马替尼术后辅助治疗的患者为治疗组,对照组为仅接受根治性手术患者,对所有患者进行随访,了解其复发转移情况。采用Kaplan-Meier法估算患者无复发生存率,同时用COX风险比例模型计算风险比及95%置信区间。结果本研究回顾性分析了110例GIST患者,其中62例为中危或高危患者。治疗组32例,对照组30例,中位随访时间为25个月(13-39个月)。截至2010年6月,对照组中12(40%)例出现术后肿瘤复发转移,中危患者3例,高危9例；治疗组中3例(9.4%)出现术后复发转移,均为高危患者。肝脏为肿瘤最常见的人转移部位。治疗组1年、2年无复发生存率显著高于对照组(100% VS 83.3%, 95.7% VS 60.0%, P=0.002, HR=0.164)。结论对于接受根治性手术的中危或高危胃肠道间质瘤患者,伊马替尼能显著延长患者的无复发生存时间。更多还原

【Abstract】 ObjectiveTo evaluate the adjuvant therapeutic effect of imatinib in intermediate or high risk gastrointestinal stromal tumors (GISTs) after radical resection.MethodsThe intermediate or high risk GIST patients between 2007.4 and 2009.6 were retrospectively reviewed. Kaplan-Meier and Cox proportion hazards regression model were used to analyze recurrence-free survival (RFS) and hazard ratio (HR).ResultsFinally, one hundred and ten patients were reviewed, and sixty two were intermediate or high risk GIST patients. The sample size of study group and control group was 32 and 30 respectively. The median follow-up time was 25 months (range 13-39 months). Twelve patients (40%) in control group had tumor recurrence, of which three were intermediate risk and nine were high risk; three patients (9.4%) in study group had tumor recurrence, all of which were high risk. The liver was the most frequent site of tumor metastasis. The recurrence-free survival (RFS) at 1 and 2 years were higher in the study group (100% VS 83.3%,95.7% VS 60.0%, P=0.002, HR=0.164), especially at the high risk GIST patients. ConclusionsThe patients classified into intermediate or high risk according to modified risk stratification can get the beneficial from adjuvant imatinib therapy.更多还原